The Nicotine Policy Experiment: What 20 Years of Divergent National Strategies Teaches Us

The global nicotine policy landscape is a natural experiment—a set of parallel policy paths pursued simultaneously by different countries, generating evidence about which approaches work and which don't. The UK embraced vaping as a harm reduction tool, integrating it into the National Health Service's smoking cessation strategy. Australia took the opposite approach, classifying nicotine vaping products as prescription-only medicines and making access as difficult as possible. Sweden relied on snus—a traditional oral tobacco product—to displace cigarettes. The United States vacillated between restriction and authorization, producing a regulatory environment that is simultaneously hostile to reduced-risk products and incapable of eliminating them. **Twenty years into this natural experiment, the results are in: the countries that embraced harm reduction have the fastest-declining smoking rates. The countries that rejected it have the slowest. The pattern is consistent, the evidence is accumulating, and the policy implications are being ignored by the institutions that should be most attentive to them.**

**The UK results are the most extensively documented.** Since Public Health England's landmark 2015 review, the UK has encouraged smokers to switch to vaping, provided vaping products through NHS stop-smoking services, and communicated clearly that vaping is substantially less harmful than smoking. The result: UK smoking prevalence has fallen from approximately 20% in 2011 to below 13% in 2023—one of the fastest declines in the world. Youth vaping rates have increased but remain below rates in countries with more restrictive policies, and youth smoking rates have continued to decline. **The feared unintended consequences—gateway effects, renormalization, youth epidemics—have not materialized. The intended consequence—accelerated smoking cessation—has.**

**The Australian results are the mirror image.** Australia's prescription-only model for nicotine vaping products, implemented in 2021, was designed to restrict vaping to medically supervised cessation and to prevent youth uptake. The result: smoking prevalence has declined more slowly than in the UK, a substantial black market for vaping products has emerged, and an estimated 1.2 million Australian vapers obtain their products through illicit channels. **The prescription model has not achieved its intended effect—restricting vaping to medical supervision—and has produced unintended consequences—a thriving black market, continued smoking, and a population of vapers who are obtaining products of unknown safety from unregulated sources.**

**Sweden provides the longest-running evidence base.** Swedish men have used snus instead of cigarettes for decades, and the result is the lowest male smoking prevalence and the lowest male lung cancer mortality in Europe. The Swedish experience demonstrates that a population-level shift from combustible to non-combustible nicotine products is achievable, sustainable, and enormously beneficial to public health—and that the shift does not require eliminating nicotine use. **Sweden is the proof of concept for tobacco harm reduction—and the global tobacco control community has spent decades ignoring it because the Swedish model accepts continued nicotine use, which is incompatible with the abstinence framework that dominates global tobacco control.**

**The United States provides the cautionary example.** The US has simultaneously restricted vaping (through the PMTA process and state-level flavor bans) and sustained a market for combustible cigarettes (through the grandfathering of cigarettes in the Tobacco Control Act and the MSA's financialization of cigarette revenue). The result is the worst of both worlds: a restricted reduced-risk market that limits smokers' access to alternatives, and a protected cigarette market that sustains the most harmful form of nicotine use. **The US is not following the evidence. It is following the political and institutional dynamics that the evidence, increasingly, contradicts.**

**💬 Which country's approach to nicotine policy do you think is closest to getting it right—the UK's harm reduction model, Australia's prescription model, Sweden's snus tradition, or the US's conflicted middle ground?** And what would it take for the evidence from these natural experiments to actually change policy?